Wednesday, 26 August 2026European Markets

INDLE FIN.ENTREPR. Stock Slides 9% So Far On Tuesday, Underperforms Market

Loading stream...

(vianews) - shares of indle fin.entrepr. (cac 40: infe.pa) slid 9.56% to €61.50 at 11:57 est on tuesday, after two consecutive sessions in a row of losses. cac 40 is falling 0.04% to €7,384.10, after five consecutive sessions in a row of gains. this seems, up until now, a somewhat down trend exchanging session today.

about indle fin.entrepr.

compagnie industrielle et financière d'entreprises sa operates as a construction company in france. it undertakes maritime and river, underwater, structures and civil engineering, buildings, and other special works. the company also develops real estate properties. compagnie industrielle et financière d'entreprises sa was founded in 1913 and is headquartered in saint-herblain, france. the company is a subsidiary of alfred de musset sas.

earnings per share

as for profitability, indle fin.entrepr. has a trailing twelve months eps of €6.45.

pe ratio

indle fin.entrepr. has a trailing twelve months price to earnings ratio of 9.53. meaning, the purchaser of the share is investing €9.53 for every euro of annual earnings.

volume

today's last reported volume for indle fin.entrepr. is 50 which is 42.85% above its average volume of 35.

more news about indle fin.entrepr. (infe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com